Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules. More
- ADVERTISEMENT
-
Sponsored By:
-
Sponsored By:
- Poll of the Day
- Partners
- ADVERTISEMENT
- More Financial News
- Top 5 Zacks #1 Ranked High Yield Mutual Funds - Best of Funds
- Another Contract for KBR - Analyst Blog
- How to Beat THIS Market - Weekend Wisdom
- Promising Data on ONCY's Reolysin - Analyst Blog
- Video Game Sales Plunge in April - Analyst Blog















